Auro Laboratories Limited has submitted the Financial Results for the Quarter Ended December 31, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Auro Laboratories' Board of Directors approved the unaudited standalone financial results for the quarter and nine months ended December 31, 2025 on February 5, 2026. Revenue from operations for Q3 FY26 stood at around Rs 9.39 crore versus Rs 8.37 crore in the year-ago quarter. For the nine-month period, revenue jumped to roughly Rs 20.01 crore from Rs 11.86 crore in the prior year — about 69% growth. Profit after tax for Q3 nearly doubled to around Rs 1.55 crore from Rs 0.72 crore, while nine-month PAT surged from Rs 1.16 crore to about Rs 2.62 crore. The statutory auditor, B.L. Dasharda & Associates, issued a clean limited review report with no qualifications. The company operates in a single segment — Pharmaceuticals.
Sharp acceleration in both revenue and profit indicates strong operating momentum heading into the final quarter. Small-cap pharma stock, so liquidity remains thin, but the earnings beat is a positive signal for shareholders and could draw investor interest.